Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by Brown Brothers Harriman & Co.

Brown Brothers Harriman & Co. grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 190.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 389 shares of the medical research company’s stock after purchasing an additional 255 shares during the period. Brown Brothers Harriman & Co.’s holdings in Charles River Laboratories International were worth $72,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of CRL. DnB Asset Management AS lifted its stake in Charles River Laboratories International by 1.4% during the fourth quarter. DnB Asset Management AS now owns 8,690 shares of the medical research company’s stock valued at $1,604,000 after buying an additional 124 shares in the last quarter. Nomura Asset Management Co. Ltd. raised its holdings in shares of Charles River Laboratories International by 0.7% during the fourth quarter. Nomura Asset Management Co. Ltd. now owns 15,694 shares of the medical research company’s stock valued at $2,897,000 after acquiring an additional 102 shares during the period. New Age Alpha Advisors LLC purchased a new stake in shares of Charles River Laboratories International in the 4th quarter valued at approximately $3,429,000. Norges Bank acquired a new position in Charles River Laboratories International in the 4th quarter worth approximately $98,886,000. Finally, UniSuper Management Pty Ltd grew its position in Charles River Laboratories International by 20.7% during the 4th quarter. UniSuper Management Pty Ltd now owns 10,033 shares of the medical research company’s stock worth $1,852,000 after purchasing an additional 1,724 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Birgit Girshick bought 1,514 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now owns 55,058 shares of the company’s stock, valued at $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Morgan Stanley decreased their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. UBS Group restated a “neutral” rating and set a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Barclays lowered their target price on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 18th. Robert W. Baird reduced their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. Finally, William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. One analyst has rated the stock with a sell rating and sixteen have given a hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $189.77.

Charles River Laboratories International Stock Down 3.1 %

CRL opened at $145.82 on Wednesday. The firm has a market cap of $7.46 billion, a P/E ratio of 972.11, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The business has a 50 day moving average price of $163.95 and a 200 day moving average price of $181.92. Charles River Laboratories International, Inc. has a twelve month low of $145.66 and a twelve month high of $267.83.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same period in the prior year, the company earned $2.46 earnings per share. Research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).